Lifog

Latanoprost, the active ingredient in Lifog, is a prostaglandin analog presented as eye drops for ocular use. It lowers intra‑ocular pressure and is indicated for the treatment of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Lifog as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU quality standards and serving hospitals, pharmacies, and clinics worldwide with reliable sourcing and regulatory support. Our global logistics network ensures timely delivery and compliance with local import requirements for each destination.

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma and ocular hypertension.

- Open-angle glaucoma: reduces intra‑ocular pressure to prevent progressive optic nerve damage. - Ocular hypertension: lowers pressure to reduce the risk of developing glaucoma. - Secondary open-angle glaucoma: improves outflow in cases related to other ocular conditions. - Pseudoexfoliative glaucoma: enhances uveoscleral outflow to control pressure. - Pigmentary glaucoma: assists in managing pressure elevations associated with pigment dispersion.

Latanoprost may cause ocular and systemic reactions after administration.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation: gradual darkening of the iris. - Eye irritation: transient burning or stinging. - Blurred vision: temporary visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract requiring medical attention. - Macular edema: fluid accumulation in the retina that may affect vision. - Vision loss: sudden decrease in visual acuity. - Ocular infection: signs of infection such as discharge or pain.

Before using Lifog, consider the following safety measures.

- Monitor IOP: schedule regular intra‑ocular pressure measurements. - Avoid use in active ocular infection: postpone treatment until infection resolves. - Caution in history of uveitis: assess risk of inflammation recurrence. - Do not combine with other prostaglandin analog eye drops: may cause excessive pressure reduction. - Pregnancy and breastfeeding: safety not established; use only if benefits outweigh risks. - Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Lifog may interact with other ophthalmic agents; review the following.

Major Interactions (Avoid): - Concomitant prostaglandin analog eye drops: additive IOP lowering may cause hypotony. - Cycloplegic agents: can diminish latanoprost efficacy. - Ocular anesthetics: may increase corneal toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may heighten ocular inflammation. - Beta‑blocker eye drops: additive IOP reduction requires monitoring. - Systemic carbonic anhydrase inhibitors: monitor intra‑ocular pressure for excessive lowering.